Immunotherapy combo shows promise for tough bladder cancers
NCT ID NCT02812420
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This early-phase study tested two immunotherapy drugs, durvalumab and tremelimumab, given before surgery to patients with aggressive bladder cancer who cannot receive standard chemotherapy. The main goal was to check safety and side effects. Researchers also looked at how the drugs affect the immune system and whether they help shrink tumors before removal. The study involved 54 participants with high-risk, muscle-invasive urothelial cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.